



G.P. 1648

W/DISK

PATENT
Attorney Docket: ONV-044.01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MIAO et al.

Appl. No. 08/900,220

: Art Unit: 1648

Filed: July 24, 1997

: Examiner: T. Wessendorf

For: *Method of Treating Dopaminergic and
GABA-nergic Disorders*

: Atty Docket: ONV-044.01

BOX SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

AUG 25 PAID

GROUP 1800

LETTER OF TRANSMITTAL

Sir:

Enclosed for filing in the above-referenced application is/are the following documents:

Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; copy of Office communication; print out of Sequence Listing; computer readable (diskette) form of Sequence Listing; and acknowledgement postcard.

Applicant believes no fees are due with this submission. However, the Commissioner is authorized to charge any deficiencies to our **Deposit Account No. 06-1448**, Ref. No. ONV-044.01. A duplicate copy of this sheet is enclosed.

Should there be any questions after reviewing this paper, the Examiner is invited to contact the undersigned at (617) 832-1272.

Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service via First Class Mail, in an envelope addressed to: Box Sequence; Assistant Commissioner for Patents, Washington, D.C. 20231 on:

August 20, 1998

Date

Ariel Collazo

Respectfully submitted,
Foley, Hoag & Eliot LLP



Diana M. Steel, D.Phil
Registration No. 43,153
Agent for Applicant



#6B 9/14/98
10 Ray

PATENT
Attorney Docket: ONV-044.01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MIAO et al. :
Appl. No. 08/900,220 : Art Unit: 1648
Filed: July 24, 1997 : Examiner: T. Wessendorf
For: *Method of Treating Dopaminergic*
 and GABA-nergic Disorders : Atty Docket: ONV-044.01

CERTIFICATE OF MAILING

I hereby certify that the foregoing document is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231 on this 20 day of August, 1998.



Ariel Collazo

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

BOX SEQUENCE
Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office communication dated July 21, 1998, Applicants submit herewith a diskette and a hard copy of a corrected sequence listing as required by 37 C.F.R. §1.821(c) and (e). The content of the computer-readable diskette is identical to the hard copy of the sequence listing attached hereto on substitute pages 76-117 of the specification.

No new matter has been added.

MIAO et al.
U.S.S.N. 08/900,200
Page 2

Although we believe that no fee is required with this submission, the Commissioner is authorized to credit any overpayment or charge any deficiencies to our **Deposit Account No. 06-1448**. Two originally-executed copies of this form are being submitted.

Should there be any questions after reviewing these papers, the Examiner is invited to contact the undersigned at (617) 832-1272.

Respectfully submitted,

FOLEY, HOAG & ELIOT LLP

August 20, 1998
Date



Diana M. Steel, D. Phil.
Reg. No. 43,153

Patent Group
Foley, Hoag & Eliot LLP
One Post Office Square
Boston, MA 02109-2170

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

AUG 24 1998

1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

7. Other: _____

Applicant must provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

Please return a copy of this notice with your response.